Abstract
Rituximab was recently described also as first-line therapy of chronic graft-versus-host disease (cGvHD). We retrospectively analyzed the efficacy and safety of all patients receiving rituximab for treatment of cGvHD between 2005 and 2016 at the Regensburg University transplant center with a median follow-up after rituximab therapy of 2.8 years. Responses of 29 allogeneic stem cell-transplanted patients (median age 49) with previous failure of response to steroids including one patient after donor lymphocyte infusion were assessed. Three months after rituximab application, the overall response rate was 31% (7% complete (n = 2) and 24% partial remission (n = 7)). At 12 months, overall survival was 72% (n = 21) and failure-free survival was 24% (n = 7). We further analyzed associations of rituximab response with clinical characteristics showing a higher response rate in steroid-dependent cGvHD patients (89% of 9 responding compared to steroid refractory patients (11% responding)). However, this difference was not statistically significant. Seven patients (24%) (including four lethal infectious complications) developed serious infections requiring hospitalization within 1–9 months after rituximab therapy exclusively in patients failing to respond to rituximab. In conclusion, rituximab appears to be an effective treatment of cGvHD especially in steroid dependent patients, but identification of biomarker predicting response will be crucial to avoid long-term infectious morbidity and mortality in non-responders.
Similar content being viewed by others
References
Socié G, Ritz J (2014) Current issues in chronic graft-versus-host disease. Blood 124(3):374–384. https://doi.org/10.1182/blood-2014-01-514752
Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, Palmer J, Arora M, Jagasia M, Arai S, Cutler CS, Lee SJ (2017) An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood 130(3):360–367. https://doi.org/10.1182/blood-2017-03-775767
Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565–2579. https://doi.org/10.1056/NEJMra1703472
Sarantopoulos S, Ritz J (2015) Aberrant B-cell homeostasis in chronic GVHD. Blood 125(11):1703–1707. https://doi.org/10.1182/blood-2014-12-567834
Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, Ho VT, Alyea EP, Koreth J, Blazar BR, Soiffer RJ, Antin JH, Ritz J (2009) Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 113(16):3865–3874. https://doi.org/10.1182/blood-2008-09-177840
Wang KS, Kim HT, Nikiforow S, Heubeck AT, Ho VT, Koreth J, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Cutler CS, Ritz J (2017) Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood 130(26):2889–2899. https://doi.org/10.1182/blood-2017-08-801001
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E (2006) Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108(2):756–762. https://doi.org/10.1182/blood-2006-01-0233
Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A (2009) Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 15(9):1005–1013. https://doi.org/10.1016/j.bbmt.2009.04.003
Mohty M, Marchetti N, El-Cheikh J et al (2008) Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 41(10):909–911. https://doi.org/10.1038/bmt.2008.12
Clavert A, Chevallier P, Guillaume T, Delaunay J, le Gouill S, Mahe B, Dubruille V, Gastinne T, Blin N, Moreau P, Mohty M (2013) Safety and efficacy of rituximab in steroid-refractory chronic GVHD. Bone Marrow Transplant 48(5):734–736. https://doi.org/10.1038/bmt.2012.203
Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, Miklos DB, Shulman HM, Martin PJ, Sarantopoulos S, Lee SJ, Flowers MED (2016) A randomized phase II crossover study of Imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res 22(2):319–327. https://doi.org/10.1158/1078-0432.CCR-15-1443
Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB (2012) Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 119(25):6145–6154. https://doi.org/10.1182/blood-2011-12-395970
Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, Rosenblatt J, McDonough S, Watanaboonyongcharoen P, Armand P, Koreth J, Glotzbecker B, Alyea E, Blazar BR, Soiffer RJ, Ritz J, Antin JH (2013) Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 122(8):1510–1517. https://doi.org/10.1182/blood-2013-04-495895
Malard F, Labopin M, Yakoub-Agha I, Chantepie S, Guillaume T, Blaise D, Tabrizi R, Magro L, Vanhove B, Blancho G, Moreau P, Gaugler B, Chevallier P, Mohty M (2017) Rituximab-based first-line treatment of cGVHD after allogeneic SCT. Results of a phase 2 study. Blood 130(20):2186–2195. https://doi.org/10.1182/blood-2017-05-786137
Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A (2015) Corticosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab. Biol Blood Marrow Transplant 21(9):1576–1582. https://doi.org/10.1016/j.bbmt.2015.04.023
Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S (2017) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130(21):2243–2250. https://doi.org/10.1182/blood-2017-07-793786
George L, George B, Gottlieb DJ, Hertzberg M, Fernandez-Peñas P (2012) Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 47(5):737–738. https://doi.org/10.1038/bmt.2011.150
Gillissen MA, de Jong G, Levie SE, Yasuda E, Bakker AQ, Evers LM, Pals ST, Huisman C, van Helden PM, Spits H, Hazenberg MD (2016) AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses. Bone Marrow Transplant 51(9):1245–1248. https://doi.org/10.1038/bmt.2016.90
Gillissen MA, Kedde M, Gd J et al (2018) AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses. Blood 131(1):131–143. https://doi.org/10.1182/blood-2017-02-768762
Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, Hall AM, Flowers MED, Schultz KR, Vogelsang G, Pavletic S (2015) Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response criteria working group report. Biol Blood Marrow Transplant 21(6):984–999. https://doi.org/10.1016/j.bbmt.2015.02.025
Schoemans HM, Lee SJ, Ferrara JL et al (2018) EBMT-NIH-CIBMTR task force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 53:1401–1415. https://doi.org/10.1038/s41409-018-0204-7
Zaja F, Bacigalupo A, Patriarca F et al (2007) Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40(3):273–277. https://doi.org/10.1038/sj.bmt.1705725
Olivieri J, Manfredi L, Postacchini L, Tedesco S, Leoni P, Gabrielli A, Rambaldi A, Bacigalupo A, Olivieri A, Pomponio G (2015) Consensus recommendations for improvement of unmet clinical needs--the example of chronic graft-versus-host disease: a systematic review and meta-analysis. Lancet Haematol 2(7):e297–e305. https://doi.org/10.1016/S2352-3026(15)00095-2
von Bonin M, Oelschlägel U, Radke J, Stewart M, Ehninger G, Bornhauser M, Platzbecker U (2008) Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 86(6):875–879. https://doi.org/10.1097/TP.0b013e318183f662
Dubovsky JA, Flynn R, Du J et al (2014) Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 124(11):4867–4876. https://doi.org/10.1172/JCI75328
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was funded by the german research foundation, collaborative research center 221, individual project B10 (Daniel Wolff).
Conflict of interest
Daniel Wolff received honoraria from Mallinckrodt, Novartis, Shire and Neovii. All other authors declare no conflict of interest.
Ethical approval
Because our study was a retrospective analysis, no additional ethical approval of the institutional committee was necessary.
Informed consent
Informed consent to receive rituximab was obtained from all individual participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Klobuch, S., Weber, D., Holler, B. et al. Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease—single center experience. Ann Hematol 98, 2399–2405 (2019). https://doi.org/10.1007/s00277-019-03768-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-019-03768-x